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Abstract
Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are the most poisonous 
substances known to mankind. It is essential to have a simple, quick and sensitive method for the 
detection and quantification of botulinum toxin in various media, including complex biological 
matrices. Our laboratory has developed a mass spectrometry-based Endopep-MS assay that is able 
to rapidly detect and differentiate all types of BoNTs by extracting the toxin with specific 
antibodies and detecting the unique cleavage products of peptide substrates. Botulinum neurotoxin 
type E (BoNT/E) is a member of a family of seven distinctive BoNT serotypes (A to G) and is the 
causative agent of botulism in both humans and animals. To improve the sensitivity of the 
Endopep-MS assay, we report here the development of novel peptide substrates for the detection 
of BoNT/E activity through systematic and comprehensive approaches. Our data demonstrate that 
several optimal peptides could accomplish 500-fold improvement in sensitivity compared to the 
current substrate for the detection of both not trypsin-activated and trypsin-activated BoNT/E toxin 
complexes. A limit of detection of 0.1 mouseLD50/mL was achieved using the novel peptide 
substrate in the assay to detect not trypsin-activated BoNT/E complex spiked in serum, stool and 
food samples.
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 Introduction
The neurotoxins produced by Clostridium botulinum (Botulinum Neurotoxins, BoNT) are 
the most poisonous substances known to mankind. The life threatening diseases caused by 
these toxins include food-borne botulism, infant botulism, wound botulism, and adult 
intestinal colonization[1]. BoNTs also constitute a potential biological weapon as they are 
easy to produce[2]. On the other hand, botulinum toxins have been used for therapeutic or 
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aesthetic applications[3]. For all these applications, it is essential to have a simple, quick and 
sensitive method for the detection and quantification of botulinum toxin in various media, 
including complex biological matrices.
The botulinum neurotoxins are synthesized as single chain polypeptides of 150 kDa which 
undergo proteolytic cleavage to generate active holotoxins constituted of two protein sub-
units linked by a disulfide bond: a heavy chain (100 kDa) involved in target binding and a 
light chain (50 kDa) responsible for the toxicity through its peptidase activity[4]. In fact, the 
BoNTs belong to a family of zinc-dependent metallopeptidases. They cleave neuronal 
proteins involved in the exocytosis of neurotransmitters, such as SNAP-25, synaptobrevin 
and syntaxin, at the site specific to each toxin[5; 6]. This cleavage consequently blocks the 
release of neurotransmitter molecules at the neuromuscular junction ultimately leading to 
flaccid paralysis of muscle activity.
The neurotoxin type E (BoNT/E) forms part of a family of seven confirmed, related 
serotypes (botulinum toxins A to G) produced by different strains of Clostridium 
botulinum[7]. BoNT/E is a neurotoxin that causes botulism in both humans and animals. 
The most common intoxication by toxin type E is associated with eating contaminated fish 
[8; 9]. BoNT/E is unique because it is released from the bacterium as a single chain and 
cleaved into an active di-chain form by unidentified host cell proteases or other exogenous 
proteases such as trypsin [10; 11]. Activation of a single chain BoNT/E by trypsin leads to 
an approximately two orders of magnitude more potent neurotoxin than the single chain 
molecule [10; 12].
The mouse bioassay is the historic method for the detection of botulinum toxins[2]. It is very 
sensitive, detecting as little as approximately 10 picograms of active toxin which is defined 
as 1 mouse LD 50 (mLD50), but the assay can be slow in obtaining final results and requires 
the sacrifice of many animals. Therefore, much effort has been undertaken to develop 
alternative in vitro endopeptidase activity assays based on BoNT’s intrinsic enzymatic 
function. Several laboratories, including ours, have developed activity methods, by 
measuring the BoNTs’ cleavage products using synthetic peptide substrates with various 
detection platforms[13].
BoNT/E cleaves specifically one of the SNARE complex proteins, SNAP-25, at the Arg180-
Ile181 bond [14]. Montecucco and coworkers revealed that the minimal length for proteolysis 
of SNAP-25 by BoNT/E includes a SNARE motif starting from Ala141 [15]. Binz and 
coworkers defined the minimal essential domain of SNAP-25 required for cleavage by 
BoNT/E as Ile156-Asp186 [16]. Through saturation mutagenesis and deletion mapping, 
Barbieri and Chen defined a short optimal cleavage domain of Met167-Asp186, where the 
subsite of Met167-Thr173 was considered as a binding domain contributing to substrate 
affinity [17; 18]. These findings led to the development of peptide substrates used in various 
in vitro activity assay platforms for the detection of the BoNT/E toxin. For instance, a 
fluorescence based assay uses a recombinant substrate consisting of the SNAP-25 sequence 
Ile134-Gly206 flanked by a green fluorescent protein (GFP) and a blue fluorescent protein 
(BFP)[19]. A 70-mer peptide of Val137-Gly206 as a substrate is included in an immuno-assay 
where the cleavage product was detected by a specific antibody [20]. The sequence of 
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Ala141-Gly206 with a fluorescent tag on either terminus of the peptide formed a substrate 
included in the BoTestTM kit that uses Förster resonance energy transfer (FRET) technology 
to detect BoNT/E activity [21]. A 61-mer peptide consisting the sequence of Met146-Gly206 
is reported in a capillary electrophoresis method [22]. The peptides of Ile156-Asp186 and 
Ile156-Thr190 are used in a mass spectrometry-based Endopep-MS assay developed in our 
laboratory[23; 24]. During the preparation of this manuscript, a new paper published 
claimed the peptide of Met167-Asp186 and its derivative with two Met replaced by Nle 
residues were effective substrates for the Endopep-MS platform[25]. This report described 
the development of a novel peptide substrate to improve the sensitivity of the Endopep-MS 
assay for the determination of BoNT/E catalytic activity. Through comprehensive 
optimization using approaches of truncation, deletion, single and multiple substitution and 
other modifications, we have developed several highly efficient peptides that showed more 
than a 500-fold improvement than the substrate currently used in the Endopep-MS assay.
 Materials and method
All chemicals were obtained from Sigma–Aldrich (St. Louis, MO) except where indicated 
otherwise. Fmoc-amino acid derivatives and peptide synthesis reagents were purchased from 
EMD Chemicals, Inc. (Gibbstown, NJ) or Protein Technologies (Tucson, AZ). Isotopically 
labeled Fmoc-amino acid derivatives were purchased from Cambridge Isotope Laboratories 
(Tewksbury, MA). The complex forms of the botulinum neurotoxin without pre-activation 
and the trypsin activated BoNT/E toxin were obtained from Metabiologics (Madison, WI). 
Botulinum neurotoxin is highly toxic and appropriate safety measure is required. All BoNT 
neurotoxins were handled in a class 2 biosafety cabinet equipped with HEPA filters. 
Monoclonal antibodies were provided by Dr. James Marks at the University of California, 
San Francisco. Streptavidin coated Dynabeads were purchased from Invitrogen (Lake 
Success, NY). Serum and stool extracts were purchased from commercial source or 
collected from anonymous donors, and no demographic information was obtained (CDC 
IRB 4307).
 Peptide synthesis
All peptides were prepared in house by a solid phase peptide synthesis method using Fmoc 
chemistry on a Liberty microwave peptide synthesizer (CEM, Matthews, NC, USA) or a 
Tribute peptide synthesizer (Protein Technologies, Tucson, AZ, USA). Peptides were 
cleaved and deblocked using a reagent mixture of 95% trifluroacetic acid :2% water: 2% 
anisole:1% ethanedithiol and purified by reversed-phase HPLC using a water:acetonitrile:
0.1% TFA gradient (90-95% purity). Correct peptide structures were confirmed by MALDI 
mass spectrometry. All peptides were dissolved in deionized water as a 1 mM stock solution 
and were stored at −70°C until further use.
 Endopep-MS assay
In-solution or on-bead Endopep-MS assays were carried out as previously described [26]. In 
brief, the reaction was conducted in a 20 μL reaction volume containing 0.1 mM peptide 
substrate, 10 μM ZnCl2, 1 mg/mL BSA, 10 mM dithiothreitol, and 200 mM HEPES buffer 
(pH 7.4) at 37°C for 1 or 4 hrs. For the in-solution assays without antibody-coated beads, 
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various concentrations of BoNT/E, as indicated in the text, were directly added into the 
reaction mixture. For samples including complex matrices, the toxin spiked in matrix was 
first purified by antibodies immobilized on streptavidin beads followed by an activity assay 
as described [26].
After reaction, 2 μL of the supernatant was mixed with 20 μL of α-cyano-4-hydroxy 
cinnamic acid at 5 mg/mL in 50% acetonitrile/0.1% TFA/1 mM ammonium citrate; 2 μL of 
a 1 μM internal standard peptide (isotope labeled peptides resembling the sequence of either 
the C- or N-terminal cleavage product) was added to the solution. The formation of cleavage 
products was measured as the ratio of the isotope cluster areas of the cleavage product 
versus an internal standard.
 MS detection
Each sample was spotted in triplicate on a MALDI plate and analyzed on a 5800 MALDI-
TOF-MS instrument (Applied Biosystems, Framingham, MA). Mass spectra of each spot 
were obtained by scanning from 800 to 4000 m/z in MS-positive ion reflector mode. The 
instrument uses a Nd-YAG laser at 355 nm, and each spectrum is an average of 2400 laser 
shots.
 Results and discussion
 Optimal length of the peptide substrate of BoNT/E determined by truncation, deletion 
and mutation
Endopep-MS assay is a method using mass spectrometry, matrix assisted laser desorption 
ionization (MALDI) or electrospray ionization (ESI), to detect either one or two cleavage 
products hydrolyzed from a peptide substrate by an affinity enriched toxin. Therefore, assay 
sensitivity will not only depend on the hydrolysis efficiency (substrate binding and 
catalysis), but also rely on the ionization of cleaved peptide fragments, which is associated 
with their amino acid sequence. While different lengths of peptides including the essential 
elements for substrate binding and cleavage are applied in various in vitro BoNT activity 
assays as described above, a study on the optimal length of a peptide specifically suitable for 
the detection of BoNT/E by Endopep-MS was lacking. The peptide substrate (Pep-8 in Table 
1) currently used in the Endopep-MS assay was derived from the partial sequence of 
SNAP-25, ranging from the amino acid residues Ile156 to Thr190 [27]. To examine whether 
further improvement can be achieved by optimizing peptide length for our Endopep-MS 
assay, we systematically prepared a series of peptides with extended or shortened sequences 
from either the N-terminal or C-terminal direction of the Pep-8, where the opposite end of 
the substrate remained the same (Table 1). In order to avoid bias caused by sequence-
dependent ionization of cleavage fragments, the hydrolysis of the peptides with variable N-
termini (Pep-1 to Pep-6) was compared by measuring the formation of C-terminal cleavage 
products by MALDI-TOF-MS, while that of the C-terminal varied peptides (Pep-7 to 
Pep-14) was compared with the production of N-terminal cleavage products. For those N-
terminal truncated peptides, the longest peptide (Pep-1) with the SNAP-25 sequences of 
Ala141-Gly206 yielded the highest production of the cleavage product. When 10 or 15 N-
terminal residues were removed (Pep-2 and Pep-3), the cleavage efficiency of these two 
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substrates underwent a slight decrease. On the other hand, further deleting N-terminal 
resides (Pep-4 to Pep-6) led to a drastic reduction or non-detection of the cleavage products. 
For C-terminal truncated peptides, extending amino acid residues all the way to the last 
SNAP-25 residue at the position 206 (Pep-7) did not provide any benefit, compared to the 
activity of Pep-8 substrate which ends at position 190. Further C-terminal truncation of the 
peptides caused a steady decrease in their substrate hydrolysis (Pep-9 to Pep-14). In 
summary, Pep-1 performed the best among the tested BoNT/E substrate peptides of various 
lengths. This likely explained why the peptide itself, or with added fluoresence tags, was 
used as an efficient substrate in other studies and commercial kits (BoTest™ A/E Botulinum 
Neurotoxin Detection Kit, Biosentinel, Inc.). The large size of this peptide (7.5kDa), 
however, raised issues such as difficulty of peptide preparation and low solubility in assay 
buffers. In contrast, the molecular weight of Pep-8 (4.0kDa) is almost half of that of the 
Pep-1, but it has retained 90% of the substrate activity. For these reasons, we decided to use 
this peptide as a template for further optimization.
The next modification to optimize the substrate focused on adding or deleting single amino 
acids to or from either end of the Pep-8 in order to examine whether smaller changes in 
peptide size impact the substrate activity. As shown in Table 2, removing one or two Ile 
residues from the N-terminus of the peptide resulted in a 30 to 40% decrease in cleavage 
efficiency of the newly formed peptides (Pep-15, Pep-16). In addition, extending the 
sequence (Pep-17) by adding a glycine (residue 155 of SNAP-25) to the N-terminus led to 
reduced production of enzyme cleavage products as well. The importance of two N-terminal 
hydrophobic residues led us to speculate that the side chains of these two Ile residues might 
have some direct contact with the enzyme through a hydrophobic-hydrophobic interaction. 
An increase in the cleavage product from Pep-18, after the third Ile residue was incorporated 
into the N-terminus of Pep-8, provided some supportive evidence for this hypothesis. More 
studies attempting to address this issue will be described below.
A remarkable improvement was obtained when one or two additional SNAP-25 residues 
were extended on the C-terminus of the Pep-18. Incorporation of Arg191 and Arg191-Ile192 
into the Pep-19 and Pep-20, respectively, resulted in a 20-fold increase in the detection of the 
C-terminal cleavage products (CT-product) (Table 2). Since the N-terminal products (NT-
product) cleaved from these peptides did not show significant changes, the elevated 
measurement of the CT-product should not come from altered cleavage efficiency of the new 
substrates, but must be due to the contribution of elevated ionization efficiency of the CT-
products measured in positive ion mode by MALDI-TOF-MS, presumably directly 
associated with a positively charged Arg residue. In contrast, deletion of two C-terminal 
residues containing a positively charged Lysine from the Pep-18 led to a peptide (Pep-21) 
with reduced cleavage efficiency, indicated by a 52% production of the NT-product and 
decreased ionization of its CT-product (20%) as well.
In an attempt to shorten peptide size to improve synthesis yields and/or peptide solubility in 
the reaction buffer, internal deletions were applied on the N-terminal portion of the new 
template peptide, Pep-20. Table 3 shows that three peptides, Pep-22, Pep-23 and Pep-24, 
deleting 5 consecutive residues in different regions yielded different consequences. While 
less than 20% of the CT-product was detected from Pep-22 and Pep-23, removal of the area 
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consisting of the sequence of RHMAL in Pep-24 retained 90% substrate activity, revealing 
that the chain of RHMAL did not play a critical role in peptide binding and/or substrate 
cleavage. Further deleting several residues sequentially, flanking either end of this 5-residue 
region, produced seven new peptides, Pep-25 through Pep-31. Among these peptides, 
Pep-29, with two more residues removed, maintained a relative production of the CT-
product (88%) similar to that of the Pep-24. It was also interesting to see how a single 
residue difference significantly altered the cleavage efficiency of newly formed peptides by 
BoNT/E, for instance, Pep-28 (2%) versus Pep-29 (88%). In conclusion, this result 
demonstrated that seven internal residues (RHMALDM) within the BoNT/E peptide 
substrate seem to not participate in enzyme-substrate interaction and hence can be removed 
without significant negative impact on the substrate cleavage. To examine the viability of 
further shortening Pep-29, three new peptides (Pep-32, -33, and -34) were designed, where 
one to three C-terminal residues (T, KT and NKT) were removed but the terminal Arg 
residue was maintained. It was observed that the shortest Pep-34 turned out to be a poor 
BoNT/E substrate whereas the medium length substrate, Pep-33, retained the most substrate 
capability (Table 3). Pep-32, on the other hand, resulted in significant activity improvement 
compared to Pep-29. Pep-32 generated over 30% CT- and NT-products more than Pep-29, 
suggesting that Pep-32 possessed a higher BoNT/E cleavage efficiency, whereas the 
ionization efficiency of its CT-product remained unchanged. This peptide was then used as a 
new template for additional optimization discussed below.
 Further improvement was accomplished by single or multiple substitutions
Based on the sequence of the best substrate, Pep-32, we carried out a thorough single 
mutation study where every single residue was substituted with selected amino acids and the 
peptide mutants were tested as BoNT/E substrates. While about two-third of the mutants 
tested produced less cleavage products than the wild-type did, another one-third of the single 
mutated peptides resulted in a higher substrate efficiency, some of those showed three-fold 
or higher improvement (Fig. 1), demonstrating the power of a mutation approach for 
substrate optimization.
It was interesting to observe that a substantial improvement was accomplished when each of 
three N-terminal nonpolar Ile residues were replaced by Phe residues bearing a more 
hydrophobic side chain. This data emphasized our speculation described above that the N-
terminal residues might be involved in direct contact with the catalytic domain of the toxin 
via hydrophobic-hydrophobic interactions. Substitution with even stronger hydrophobic 
residues probably enhanced such interaction and therefore increased substrate binding 
affinity. To explore whether those putative interactions can be further improved, a series of 
peptides with the modifications of hydrophobic residues in the N-terminal region of the 
Pep-32 were developed (Fig. 2A). A slight increase in detected CT-product was observed as 
the six N-terminal residues were replaced by three Phe residues in Pep-35. On the other 
hand, reduced detection of CT-product resulted when one more Phe was added in Pep-36. 
This suggested that three hydrophobic residues still retained the special enzyme-substrate 
interaction, even in a shorter peptide, but the contact might be impacted by a longer 
hydrophobic chain. When the three N-terminal Ile residues in Pep-32 were replaced by 
residues with a more hydrophobic structure, such as Phe in Pep-37, Trp in Pep-40, and 1-Nal 
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in Pep-42, all new peptides acted as better substrates. In addition, the improvement degree, 
Pep-42 > Pep-40 > Pep-37, seems proportional to the size of the bulky side chain groups (1-
Nal > Trp > Phe, Fig. 2B). This data provided additional supportive evidence for the 
suggestion of a hydrophobic interaction between the BoNT/E enzyme and the peptide 
substrates. Moreover, the hydrophobicity effect was also demonstrated by the fact that the 
double Trp substitution (Pep-39) displayed higher cleavage efficiency than the triple Phe 
substituted peptide (Pep-37) did, and the triple Trp replacement in Pep-40 resulted in better 
substrate efficiency than the double-Trp one in Pep-39, presumably due to the difference of 
their combined hydrophobicity. A similar effect was also observed by comparing the 
cleavage of the double 1-Nal peptide (Pep-41) with the triple Trp and triple 1-Nal ones 
(Pep-40 and Pep-42, respectively). Furthermore, significantly reduced substrate cleavage by 
BoNT/E on the peptides with a cluster of five Phe residues (Pep-38) or four 1-Nal residues 
(Pep-43) suggested that the size of the hydrophobic cluster on the N-terminus of a substrate 
was not unrestricted. In other words, the space of the putative hydrophobic pocket in the 
catalytic domain of the toxin was limited and it might not allow the placement of more than 
three very bulky side chain groups. More study is needed to further confirm or address this 
proposed hydrophobic interaction between BoNT/E protease and its peptide substrate.
Additional effort on further substrate optimization was put on combining single mutations 
that showed enhanced detection of BoNT/E cleavage products. Since some single mutations 
may alter the conformation of mutated peptides or intra- and inter molecular interactions, 
and hence the property of their substrate binding and/or catalysis, it is not realistic to expect 
a best substrate can be obtained by simply placing together in a single sequence all good 
single substitutions derived from the studies described above. However, it is reasonable to 
believe that some combinations of the single mutations may achieve an augmented effect. 
For this purpose, new peptides were designed where different combinations of the amino 
acid substitutions, derived from the studies of single mutation and N-terminal modifications 
described above, were incorporated into their corresponding positions of the template 
peptide (Pep-32). In addition, some unnatural amino acids, such as homoarginine (hR), and 
terminal modifications, such as C-terminal amidation, were introduced in some peptides in 
order to increase peptide stability and reduce their susceptibility to non-specific cleavage by 
other proteases (e.g. Trypsin) present in biological samples. Table 4 lists some of such 
modified peptides (Pep-45 to Pep-62) that showed a comparable or better substrate 
performance than that of the peptide with a single internal substitution (Pep-44). While some 
multiple substituted peptides (e.g. Pep-45, Pep-46, Pep-48 or Pep-55) exhibited similar or 
slightly improved detection sensitivity, in terms of the detection of the C-terminal cleavage 
products, many of the novel peptides achieved a significant improvement with 50% to 300% 
increase in the CT-product detection, revealing that added benefit on assay sensitivity could 
be obtained by combining sound single mutations. Among four candidates displaying three-
fold improvement over Pep-44, Pep-59 proved to be the best in solubility and the Pep-62 
showed highest resistance toward undesired cleavage by nonspecific proteases present in 
clinical samples (Data not shown). The substitution of the arginine at the cleavage site with 
an unnatural homoarginine residue seems to contribute to improved resistance toward the 
cleavage by nonspecific proteases such as trypsin. Therefore, these two optimal peptides 
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were selected to be used in further experiments and in routine analysis of biological samples 
for the BoNT/E detection by the Endopep-MS assay.
 Evaluation of optimized peptides as BoNT/E substrates in the Endopep-MS assay
To evaluate the outcome of the optimization for the BoNT/E substrates, Pep-59, one of the 
four best optimized peptides, was compared to Pep-8, the substrate currently used in the 
Endopep-MS assay. The substrates were hydrolyzed by two forms of BoNT/E toxins: one is 
the single chain holotoxin without pre-activation as a complex with neurotoxin-associated 
proteins, and another is the BoNT/E di-chain complex that had been activated by exposing it 
to trypsin during the manufacturing process. As shown in Table 5, the optimal peptide was 
able to detect the cleavage products at a 500-fold lower level of BoNT/E compared to the old 
peptide substrate, for both not activated and trypsin-activated BoNT/E toxin complexes, 
under the same experimental conditions, demonstrating a dramatic improvement in the assay 
sensitivity using the new peptide substrate. When testing the sensitivity of the Endopep-MS 
assay using the newly developed optimal peptide, the limit of detection of 0.1 mLD50 
(1pg/mL or 5.5 attomole/mL) was accomplished for the detection of not trypsin-activated 
BoNT/E toxin complex spiked in serum and stool extract, two common biological matrices 
used for botulism clinical samples, after a 4 hour cleavage reaction (Fig. 3, S/N > 3). This 
represent an assay sensitivity 10-fold lower than that measured by a traditional mouse 
bioassay. The specificity of the optimal peptides was examined by exposing them to other 
serotypes of botulinum neurotoxins including type A, B, and F, and no cleavage product was 
observed (data not shown). In addition to the specific BoNT/E subtype (E3) used in the 
experiments described above, the optimized peptides also proved to be effective substrates of 
other tested BoNT/E subtypes including E1, E2, E4, E7 and the most divergent E9 (Data not 
shown).
 Conclusion
We developed novel peptide substrates for the mass spectrometry-based Endopep-MS assay 
for the detection of type E botulinum neurotoxin. The systematic and comprehensive 
optimization process included peptide terminal truncation, internal deletion, single and 
multiple substitution, terminal residue modification and incorporation of unnatural amino 
acid residues. Our data demonstrate that one of the four optimal peptides demonstrated a 
500-fold improvement in assay sensitivity than the current substrate, used for the detection 
of both not activated and trypsin-activated BoNT/E toxin complexes. The limit of detection 
for the toxin complex without pre-activation in serum, stool and food samples using the new 
substrate is 0.1 mouseLD50/mL. In addition, the troublesome nonspecific cleavage in blank 
control samples was significantly improved by incorporating an unnatural homoarginine 
residue in the cleavage site of the optimal peptides. A patent application of these optimized 
peptides has been filed and the novel peptide substrates continue to be used in our laboratory 
for routine analysis of clinical samples.
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Effect of single amino acid mutations on the detection of cleavage product of mutated 
peptide-32 by BoNT/E. The residues at BoNT/E cleavage site are underlined. X represents 
norleucine.
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(A) Cleavage efficiency of the peptides modified with N-terminal hydrophobic residues. (B) 
the structure of some hydrophobic residues. Several N-terminal residues are represented by 
letters and other identical regions of the sequences are represented by lines. O1: 1-1-
Naphthylalanine (Nal).
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Product response from the cleavage of Pep-59 by not trypsin-activated BoNT/E of various 
concentrations spiked in serum and stool matrices. Cleavage reaction condition: 37°C, 4 
hours.
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Table 1











Pep-2 151-206 EQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 75
Pep-3 156-206 IIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 89
Pep-4 161-206 RHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 28
Pep-5 166-206 DMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 19
Pep-6 171-206 IDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 0
Pep-7 156-206 IIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG 100
Pep-8
d 156-190 IIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKT 100
Pep-9 156-188 IIGNLRHMALDMGNEIDTQNRQIDRIMEKADSN 81
Pep-10 156-186 IIGNLRHMALDMGNEIDTQNRQIDRIMEKAD 68
Pep-11 156-185 IIGNLRHMALDMGNEIDTQNRQIDRIMEKA 77
Pep-12 156-184 IIGNLRHMALDMGNEIDTQNRQIDRIMEK 38
Pep-13 156-183 IIGNLRHMALDMGNEIDTQNRQIDRIME 15
Pep-14 156-182 IIGNLRHMALDMGNEIDTQNRQIDRIM 10
a
Relative cleavage rate obtained from the analysis of C-terminal cleavage products (CT-prod). Condition: 37°C, 4 hour.
b
Relative cleavage rate obtained from the analysis of N-terminal cleavage products (CT-prod).
c
The cleavage site of BoNT/E substrate is depicted in bold.
d
Pep-8 is the BoNT/E substrate currently used in Endopep-MS assay.
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Table 2










Pep-19 IIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRI 2000 100
Pep-20 IIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTR 2177 117
Pep-18 IIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKT 100 130
Pep-21 IIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSN 20 52
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Table 3















Pep-29 IIIGNL____________GNEIDTQNRQIDRIMEKADSNKTR 88 100
Pep-32 IIIGNL____________GNEIDTQNRQIDRIMEKADSNKR 117 136
Pep-33 IIIGNL____________GNEIDTQNRQIDRIMEKADSNR 91 84
Pep-34 IIIGNL____________GNEIDTQNRQIDRIMEKADSR 18 36
Deleted amino acid residues from the Pep-20 are depicted in underscore.
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Table 4
Effect of multiple mutations on the cleavage of modified peptides by BoNT/E toxin*.
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Table 5









Pep-8 not activated 100 0.40 1
Pep-59 not activated 1 2.35 581
Pep-8 activated 0.16 1.07 1
Pep-59 activated 0.0016 5.48 511
*
The specific activities of activated and not activated BoNT/E was provided by the manufacturer. Cleavage reactions were conducted at 37°C for 1 
hour.
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